Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8818MR)

This product GTTS-WQ8818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8818MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9608MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ1900MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ5039MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ11878MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ6445MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ10787MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW